Vol 2, No 3 (1998)
Original paper
Published online: 2000-03-08
Get Citation

The Effects of Simvastatin and Bisoprolol Therapy on the Lipids in Serum, Hepatic Biotransformation in Patients with Essential Hypertension and Hypercholesterolaemia Type ll

Marlena Broncel, Halina Adamska-Dyniewska, Julita Chojnowska-Jezierska
Nadciśnienie tętnicze 1998;2(3):159-165.
Vol 2, No 3 (1998)
Prace oryginalne
Published online: 2000-03-08

Abstract


Introduction The aim of the study was to estimate the hypolipemic interaction between simvastatin and bisoprolol during treatment of these drugs the patients with primary mild hypertension and dyslipidemia type II.
Methods The study was undertaken in 43 patients (pts) with arterial hypertension (women: 18, men: 25, age 42-68). Patients were divided in two groups: I group-included 20 pts with basal total cholesterol (TC) > 270 mg/dl and LDL-cholesterol (LDL-C) > 170 mg/dl. After one-month run in period on hypolipemic diet they were treated firstly for 3 months with simvastatin (10-20 mg/daily) after that bisoprolol (5-10 mg/daily) was added for the next 3 months. II group - 23 pts with basal TC between 200 and 270 mg/dl; LDL-C between 130 and 170 mg/dl were given bisoprolol at the same dosage for 3 months. The rate of hepatic metabolism was estimated by antipyrine test.
Results In group I after simvastatin therapy TC and LDL-C levels decreased significant. Added of bisoprolol caused the further significant decreasing of TC and LDL-C. In group II bisoprolol caused nonsignificant decreasing of TC, LDL-C and HDL-cholesterol and increasing of triglicerydes. In both groups we didn't observed significant changes of antipyrine test.
Conclusions Bisoprolol doesn't change the hypolipemic efficacy of simvastatin and it is observed the positive effects therapy simvastatin with bisoprolol on lipids and hepatic biotransformation in patients with hypertension and hypercholesterolaemia type II.

Abstract


Introduction The aim of the study was to estimate the hypolipemic interaction between simvastatin and bisoprolol during treatment of these drugs the patients with primary mild hypertension and dyslipidemia type II.
Methods The study was undertaken in 43 patients (pts) with arterial hypertension (women: 18, men: 25, age 42-68). Patients were divided in two groups: I group-included 20 pts with basal total cholesterol (TC) > 270 mg/dl and LDL-cholesterol (LDL-C) > 170 mg/dl. After one-month run in period on hypolipemic diet they were treated firstly for 3 months with simvastatin (10-20 mg/daily) after that bisoprolol (5-10 mg/daily) was added for the next 3 months. II group - 23 pts with basal TC between 200 and 270 mg/dl; LDL-C between 130 and 170 mg/dl were given bisoprolol at the same dosage for 3 months. The rate of hepatic metabolism was estimated by antipyrine test.
Results In group I after simvastatin therapy TC and LDL-C levels decreased significant. Added of bisoprolol caused the further significant decreasing of TC and LDL-C. In group II bisoprolol caused nonsignificant decreasing of TC, LDL-C and HDL-cholesterol and increasing of triglicerydes. In both groups we didn't observed significant changes of antipyrine test.
Conclusions Bisoprolol doesn't change the hypolipemic efficacy of simvastatin and it is observed the positive effects therapy simvastatin with bisoprolol on lipids and hepatic biotransformation in patients with hypertension and hypercholesterolaemia type II.
Get Citation

Keywords

bisoprolol; simvastatin; lipids; antipyrine test

About this article
Title

The Effects of Simvastatin and Bisoprolol Therapy on the Lipids in Serum, Hepatic Biotransformation in Patients with Essential Hypertension and Hypercholesterolaemia Type ll

Journal

Arterial Hypertension

Issue

Vol 2, No 3 (1998)

Article type

Original paper

Pages

159-165

Published online

2000-03-08

Page views

729

Bibliographic record

Nadciśnienie tętnicze 1998;2(3):159-165.

Keywords

bisoprolol
simvastatin
lipids
antipyrine test

Authors

Marlena Broncel
Halina Adamska-Dyniewska
Julita Chojnowska-Jezierska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl